The Children's Research Institute
For 45 years, clinicians around the nation have been offering the parents of pediatric patients diagnosed with diffuse intrinsic pontine glioma (DIPG) the same grim prognosis. Now, researchers at Children’s National are seizing the opportunity to change that narrative, by exploring the genetic mutations associated with this disease to unlock the possibility of new therapies.
With the generous support of the Gilbert Family Foundation, we have established a strong research neurofibromatosis program that addresses both molecular pathogenesis and novel therapeutic approach to eurofibromatosis and glioma associated with the mutations in the most prevalent neurofibromatosis gene (NF1). In addition, our researchers are identifying novel treatments for meduloblastoma and other brain tumor lesions using novel animal models, and searching for biomarkers for therapeutic responses and prognosis through proteomic and genomic approaches.
Our immunology program emphasizes regulation of inflammation and its relevance to hematopoiesis, innate and adaptive immune responses in cancer and autoimmune diseases. The leukemia research programs emphasis on novel animal models for leukemia and leukemia stem cells. Our researchers not only elucidate fundamental mechanisms in immune responses and leukemia development, but also identify novel therapeutics, and that, in collaboration with the clinical oncology program, are being explored for patient care in investigator-initiated clinical trials.
This program collect cancer patients’ samples to mind genetic alterations to, identify drugs that may offer cure for patients, identify genetic polymorphism that may affect to therapeutic regimen, and establish personalized cancer models that can be used to identify new drugs for cancer treatments.
This program combines preclinical investigation and investigator-initiated clinical trials. Our researchers are pioneering new cellular therapeutic approaches for treatment of cancer, graft vs host diseases, infectious diseases and autoimmune diseases.
The clinical oncology program at Children’s National has 20 faculty members who are engaged in clinical research. The program participates in several research consortia including the Children’s Oncology Group (COG), Pediatric Brain Tumor Consortium (PBTC), Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium (TACL), the Cooperative Ependymoma Research Network (CERN), and the North American Consortium for Histiocytosis.